MetaCap

Pharvaris N.V. (PHVS) vs Arcus Biosciences (RCUS)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Pharvaris N.V. (PHVS) has outperformed Arcus Biosciences (RCUS) over the past year, gaining 26.0% versus a loss of 29.2%. Over five years, PHVS leads with a +131.3% price change compared with -66.3% for RCUS. Arcus Biosciences is the larger company by market cap ($2.25 billion vs $2.21 billion), about 1.0 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

PHVS+25.98%RCUS-29.16%
+61%+14%-33%
Nov 21, 20251 yearNov 20, 2026
PHVS+100.90%RCUS-67.15%
+156%+28%-99%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

PHVS versus RCUS key metrics
MetricPHVSRCUS
Share price$31.28$15.62
Market cap$2.21B$2.25B
1-day change-1.20%-1.01%
YTD return+12.72%-34.45%
1-year return+25.98%-29.16%
5-year return+131.28%-66.31%
EPS (TTM)$-3.13$-3.64
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)—$247.00M
Revenue growth (YoY)—-4.26%
Net income (latest FY)$-25.99M$-353.00M
Operating margin—-156.28%
Net margin—-142.91%
52-week high$43.25$31.74
52-week low$23.15$15.56
Distance from 52-week high-27.68%-50.78%
Analyst consensusstrong_buystrong_buy
Avg. price target upside+86.29%+162.48%
Average volume756.20K1.85M
Shares outstanding70.79M143.99M
Employees168601
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • PHVS has outperformed RCUS by 55.1 percentage points over the past year.

About Pharvaris N.V.

PHVS stock →

Pharvaris N.V., a late-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases with unmet needs covering angioedema and other bradykinin-mediated diseases. The company develops deucrictibant, a small molecule bradykinin B2-receptor antagonist to treat attacks due to bradykinin-mediated angioedema, including hereditary angioedema (HAE) and acquired angioedema due to C1-inhibitor deficiency (AAE-C1INH), which is in phase 3, as well as in phase 3 trials for treatment and prophylaxis of HAE attacks; and extended-release tablet and immediate-release capsule formulation of deucrictibant.

Health Care · Biotechnology: Pharmaceutical Preparations · 168 employees

About Arcus Biosciences

RCUS stock →

Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. The company's development product portfolio includes Casdatifan, a HIF-2a inhibitor for the treatment of kidney cancer; Domvanalimab, an anti-TIGIT antibody, which is in Phase 2 and Phase 3 clinical trial for lung and gastrointestinal cancers; and Zimberelimab, an anti-PD-1 antibody.

Health Care · Biotechnology: Pharmaceutical Preparations · 601 employees

PHVS vs RCUS FAQ

Which is bigger, Pharvaris N.V. or Arcus Biosciences?

Arcus Biosciences (RCUS) is larger, with a market capitalization of $2.25B compared with $2.21B for Pharvaris N.V. (PHVS).

Which stock has performed better over the past year, PHVS or RCUS?

PHVS returned +25.98% over the past 12 months, compared with -29.16% for RCUS (price return, excluding dividends). Past performance does not predict future results.

Are Pharvaris N.V. and Arcus Biosciences in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons